中国当代医药2026，Vol.33Issue(21)：26-30,5.DOI:10.3969/j.issn.1674-4721.2026.21.06
奥曲肽联合美罗培南治疗脓毒症合并重度急性呼吸窘迫综合征对患者肺血管阻力及T淋巴细胞亚群的影响
Effect of Octreotide combined with Meropenem on pulmonary vascular resistance and T lymphocyte subsets in patients with sepsis complicated by severe acute respiratory distress syndrome
摘要
Abstract
Objective To investigate the effects of Octreotide combined with Meropenem on pulmonary vascular resistance and T lymphocyte subsets in patients with sepsis complicated by severe acute respiratory distress syndrome.Methods A to-tal of 130 patients with sepsis complicated by severe acute respiratory distress syndrome admitted to Dongxin Fifth Hospital from January 2023 to January 2025 were selected as the study subjects.They were divided into the control group(65 cases)and the observation group(65 cases)using random number table method.The control group was treated with Meropenem alone,while the observation group received a combination of Octreotide and Meropenem.Both groups were treated for 7 days.The clinical efficacy rate,adverse reactions,and differences in pulmonary vascular resistance indicators and T lymphocyte subset levels before and after treatment were compared between the two groups.Results Five cases were lost to follow-up in both the control and observation groups,with 60 cases ultimately were included in each group.The clinical efficacy rate of the observation group was higher than that of the control group,with a statistically significant difference(P＜0.05).After treatment,pulmonary vascular resistance(PVR),pulmonary vascular permeability index(PVPI),and extravas-cular lung water index(EVLWI)in both groups were lower than those before treatment,and the levels of PVR,PVPI,EVLWI in the observation group were lower than those in the control group,with statistically significant differences(P＜0.05).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+ratio in the observation group were higher than those in the control group,while the CD8+level in the observation group was lower than that in the control group,with statis-tically significant differences(P＜0.05).There was no statistically significant difference in the total incidence of adverse re-actions between the two groups during treatment(P＞0.05).Conclusion Octreotide combined with Meropenem effectively reduces pulmonary vascular resistance and aids in the recovery of the immune system in patients with sepsis complicated by severe acute respiratory distress syndrome,demonstrating good clinical efficacy.关键词
奥曲肽/美罗培南/脓毒症/重度急性呼吸窘迫综合征/肺血管阻力/T淋巴细胞亚群Key words
Octreotide/Meropenem/Sepsis/Severe acute respiratory distress syndrome/Pulmonary vascular resistance/T lymphocyte subsets分类
医药卫生引用本文复制引用
姜建泽,黄丽华,朱强,杨龙辉..奥曲肽联合美罗培南治疗脓毒症合并重度急性呼吸窘迫综合征对患者肺血管阻力及T淋巴细胞亚群的影响[J].中国当代医药,2026,33(21):26-30,5.基金项目
江西省卫生健康委科技计划项目(202120112、202212784). （202120112、202212784）
